Dicot Pharma reported a wider net loss in Q1 2025 as clinical activity increased, but secured strong liquidity through a 96% warrant exercise. The phase 2a study for LIB-01 remains on track, with preparations for further clinical development underway.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.